Document resource
Recent studies have indicated that Janus kinase inhibitors (JAKi) exert context-dependent immunomodulatory effects in cancer immunotherapy. In this rapid response, we comment on the prospective cohort study by Habib et al, which evaluates JAKi for steroid-refractory or life-threatening immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). The study demonstrated a clinical remission rate of 70.8%, with notable activity in myocarditis and inflammatory arthritis. Although JAK inhibition has historically raised concern due to the central role of JAK-signal transducer and activator of transcription (STAT) signaling in interferon-mediated antitumor immunity, emerging clinical data indicate more nuanced effects influenced by timing, dosing, and immune context. This framework may help explain the observed efficacy of JAKi in controlling severe irAEs without an apparent excess of opportunistic infections. We also emphasize unresolved safety considerations, including thromboembolic risk and disease progression during follow-up. Given the clinical heterogeneity of the cohort and the limited oncologic detail, further prospective studies with stratified and time-to-event analyses are needed to better define the role of JAK inhibition in balancing irAE control and antitumor immunity.